| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g | |||
| Other Sizes |
Purity: ≥98%
Nefiracetam (DZL-221; DM9384; DZL221; DM 9384; Translon) is a potent GABAergic, cholinergic, and monoaminergic neuronal system enhancer for Ro 5-4864-induced convulsions. It is a nootropic (cognition-enhancing) agent with antidementia activity. Nefiracetam at a concentration of 1 μM increases a long-lasting component of calcium channel currents two-fold without affecting a transient component. Nefiracetam induces a short-term depression of ACh-evoked currents at submicromolar concentrations (0.01–0.1 μM) and a long-term enhancement of the currents at micromolar concentrations (1–10 μM).
| Targets |
L-type calcium channels (dihydropyridine-sensitive) [1]
Pertussis toxin-sensitive inhibitory G-proteins (G0/Gi) [1] cAMP-dependent processes [1] |
|---|---|
| ln Vitro |
In vitro activity: Nefiracetam at a concentration of 1 μM increases a long-lasting component of calcium channel currents two-fold without affecting a transient component. Nefiracetam induces a short-term depression of ACh-evoked currents at submicromolar concentrations (0.01–0.1 μM) and a long-term enhancement of the currents at micromolar concentrations (1–10 μM). Nefiracetam interacts with PKA and PKC pathways, which may explain a cellular mechanism for the action of cognition-enhancing agents. Lower (submicromolar) concentrations of the nootropic Nefiracetam reduces ACh-evoked currents to 30% (0.01 μM) and 38% (0.1 μM) of control after a 10-minute treatment. In primary cultures of rat hippocampal neurons, nefiracetam increases the rate of nicotine-sensitive miniature excitatory postsynaptic currents. Nefiracetam induces a long-lasting facilitation of synaptic transmission in both the CA1 area and the dentate gyrus of rat hippocampal slices, and the facilitation is inhibited by α-bungarotoxin and mecamylamine. Nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. In NG108-15 cells using whole-cell patch-clamp, Nefiracetam (DM-9384) at 1 μM increased long-lasting calcium channel currents (Ba2+ currents) two-fold (204.8±12.9% of control, n=9) without affecting transient component [1] Dose-response relationship showed a bell-shaped curve with peak at 1 μM; at 0.1 μM: 123.7±7.4%; at 10 μM: 136.2±5.9%; at 100 μM: 82.5±11.8% (inhibition) [1] Aniracetam showed similar but less potent effects (at 1 μM: 137.6±5.1%; at 10 μM: 160.8±14.1%) [1] Dibutyryl cAMP (1 mM) also enhanced currents, and the effects of nefiracetam and db-cAMP were not additive beyond saturation [1] The currents enhanced by nefiracetam were markedly reduced by nifedipine (10 μM), an L-type calcium channel blocker [1] Cells treated with pertussis toxin (500 ng/ml, >20 h) became insensitive to nefiracetam (relative current amplitude 103.1±3.2%, n=15) [1] Nefiracetam (DM-9384) (1 μM) significantly elevated cAMP levels in NG108-15 cells [1] |
| ln Vivo |
Nefiracetam administered orally inhibits Ro 5-4864-induced convulsions in EL mice. Nefiracetam also efficiently inhibits Ro 5-4864-induced convulsions in DDY mice at doses higher than 10 mg/kg. Nefiracetam administered daily 1 hour before each training session facilitates the acquisition process of the avoidance response.
|
| Cell Assay |
NG108-15 cells (neuroblastoma × glioma hybrid) were cultured and differentiated with 2% DMSO added to culture medium (90% Dulbecco's Modified Eagle's Medium + 10% fetal calf serum) for 5-7 days before use [1]
Whole-cell patch-clamp recording: patch electrodes (2-8 MΩ) were placed onto cell surface, membrane ruptured by suction or high-frequency train pulse; cells were voltage-clamped; external solution contained (mM): BaCl2 50, NaCl 30, CsCl 5, TEA-Cl 25, glucose 25, TTX 0.5 μM, HEPES 10 (pH 7.4 with CsOH); internal solution contained (mM): Cs-glutamate 130, MgCl2 2.5, glucose 5, PIPES 10 (pH 7.0 with NaOH); experiments at room temperature (22-25°C); currents induced by step depolarizations from holding potential of -80 mV or -50 mV; long-lasting currents measured at end of 160 ms pulse [1] Pertussis toxin treatment: cells were treated with PTX (500 ng/ml) for >20 h (22 h in one example) to inactivate inhibitory G-proteins [1] |
| Animal Protocol |
Oral Mice
|
| Toxicity/Toxicokinetics |
At high concentration (100 μM), Nefiracetam (DM-9384) suppressed long-lasting calcium channel currents to 82.5±11.8% of control, indicating an inhibitory effect at supramaximal concentrations [1]
|
| References |
Brain Res.2000 Mar 24;859(2):255-61;Brain Res.1994 Apr 11;642(1-2):123-31.
|
| Additional Infomation |
Nefilracetam is an oxygen- and nitrogen-containing organic compound whose function is related to α-amino acids. Nefilracetam has been used in clinical trials for the treatment of Alzheimer's disease.
The nootropic action of Nefiracetam (DM-9384) on L-type calcium channels is suggested to be mediated by intracellular cyclic AMP and pertussis toxin-sensitive G-proteins, possibly by blocking tonic inhibitory influence of G-proteins on calcium channels and cAMP-dependent processes [1] Nefiracetam (DM-9384) may be a useful tool to identify factors determining aging, learning and memory; it reversed inhibitory effects of opioids on calcium channels [1] |
| Molecular Formula |
C14H18N2O2
|
|
|---|---|---|
| Molecular Weight |
246.3
|
|
| Exact Mass |
246.136
|
|
| CAS # |
77191-36-7
|
|
| Related CAS # |
|
|
| PubChem CID |
71157
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
458.5±33.0 °C at 760 mmHg
|
|
| Melting Point |
151-155°C
|
|
| Flash Point |
231.1±25.4 °C
|
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
|
| Index of Refraction |
1.594
|
|
| LogP |
1.53
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
2
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
18
|
|
| Complexity |
320
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
NGHTXZCKLWZPGK-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)
|
|
| Chemical Name |
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0601 mL | 20.3004 mL | 40.6009 mL | |
| 5 mM | 0.8120 mL | 4.0601 mL | 8.1202 mL | |
| 10 mM | 0.4060 mL | 2.0300 mL | 4.0601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.